|
WO2015038958A1
(en)
|
2013-09-13 |
2015-03-19 |
California Institute Of Technology |
Selective recovery
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
SG11201703148TA
(en)
|
2014-11-05 |
2017-05-30 |
Voyager Therapeutics Inc |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
CA3193811A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
DK3218386T3
(da)
|
2014-11-14 |
2021-06-07 |
Voyager Therapeutics Inc |
Modulatorisk polynukleotid
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
JP6754361B2
(ja)
*
|
2014-12-16 |
2020-09-09 |
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ |
若年型バッテン病のための遺伝子療法
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
AU2016366549B2
(en)
|
2015-12-11 |
2022-11-10 |
California Institute Of Technology |
Targeting peptides for directing adeno-associated viruses (AAVs)
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
US11951121B2
(en)
|
2016-05-18 |
2024-04-09 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating Huntington's disease
|
|
AU2017267665C1
(en)
|
2016-05-18 |
2023-10-05 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
CN110650673B
(zh)
|
2016-08-30 |
2024-04-09 |
加利福尼亚大学董事会 |
用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
|
|
FI3574091T3
(fi)
|
2017-01-30 |
2023-05-03 |
Brainvectis |
Ekspressiovektori kolesterolin 24-hydrolaasia varten polyglutamiinin toiston spinoserebellaariataksioiden hoidossa
|
|
MX2019012113A
(es)
|
2017-04-14 |
2020-09-10 |
Univ Nat Taiwan |
Terapia génica para la deficiencia de la aadc.
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
CN119491003A
(zh)
|
2017-05-05 |
2025-02-21 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
NETWORK EQUIPMENT TRACK GUIDE SYSTEM
|
|
TWI722310B
(zh)
*
|
2017-08-03 |
2021-03-21 |
美商航海家醫療公司 |
用於aav之遞送之組合物及方法
|
|
US20190085358A1
(en)
*
|
2017-08-25 |
2019-03-21 |
Ovid Therapeutics Inc. |
Recombinant adeno-associated vectors
|
|
US20200263199A1
(en)
*
|
2017-09-29 |
2020-08-20 |
Voyager Therapeutics, Inc. |
Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
|
|
AU2018352236B2
(en)
|
2017-10-16 |
2025-04-10 |
The Curators Of The University Of Missouri |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
KR102776626B1
(ko)
*
|
2017-10-16 |
2025-03-04 |
비게네론 게엠베하 |
Aav 벡터
|
|
US11458129B2
(en)
|
2017-11-02 |
2022-10-04 |
California Institute Of Technology |
Neurokinin antagonists and uses thereof
|
|
EP3703716A4
(en)
|
2017-11-02 |
2021-12-01 |
California Institute of Technology |
EXPRESSION OF NEUROPEPTIDES
|
|
US20190202866A1
(en)
*
|
2017-12-22 |
2019-07-04 |
William Marsh Rice University |
Viral nanoparticles and methods of use thereof
|
|
JP7430652B2
(ja)
|
2018-03-05 |
2024-02-13 |
ザ チルドレンズ メディカル センター コーポレーション |
蝸牛および前庭細胞に核酸を送達するための組成物および方法
|
|
EP3774853A1
(en)
*
|
2018-03-30 |
2021-02-17 |
The Board of Trustees of the Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
|
|
US12091435B2
(en)
|
2018-04-03 |
2024-09-17 |
Ginkgo Bioworks, Inc. |
Antibody-evading virus vectors
|
|
CA3094311A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
WO2019195423A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
US12121563B2
(en)
|
2018-04-09 |
2024-10-22 |
Allen Institute |
Rescuing voltage-gated sodium channel function in inhibitory neurons
|
|
WO2019200016A1
(en)
|
2018-04-10 |
2019-10-17 |
President And Fellows Of Harvard College |
Aav vectors encoding clarin-1 or gjb2 and uses thereof
|
|
WO2019198084A1
(en)
*
|
2018-04-12 |
2019-10-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-aging compositions and methods of use
|
|
WO2019210325A1
(en)
|
2018-04-27 |
2019-10-31 |
Rocket Pharmaceuticals, Ltd. |
Gene therapy for cns degeneration
|
|
US20210230632A1
(en)
*
|
2018-05-15 |
2021-07-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US12319929B2
(en)
|
2018-05-15 |
2025-06-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of Parkinson's disease
|
|
US12060567B2
(en)
|
2018-06-13 |
2024-08-13 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (UTR) for AAV production
|
|
JP2021530218A
(ja)
|
2018-07-11 |
2021-11-11 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
血液脳関門を超える薬剤の送達のための方法および組成物
|
|
US20210355454A1
(en)
|
2018-07-24 |
2021-11-18 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
EP3830107A2
(en)
|
2018-08-03 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
CN113966399A
(zh)
|
2018-09-26 |
2022-01-21 |
加州理工学院 |
用于靶向基因疗法的腺相关病毒组合物
|
|
CA3114621A1
(en)
|
2018-09-28 |
2020-04-02 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
WO2020072683A1
(en)
|
2018-10-02 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
US20210348242A1
(en)
|
2018-10-04 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
US20210348194A1
(en)
|
2018-10-05 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
CA3115652A1
(en)
|
2018-10-08 |
2020-04-16 |
Allen Institute |
Artificial expression constructs for selectively modulating gene expression in interneurons
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
JP2022505106A
(ja)
|
2018-10-15 |
2022-01-14 |
ボイジャー セラピューティクス インコーポレイテッド |
バキュロウイルス／Ｓｆ９システムにおけるｒＡＡＶの大規模産生のための発現ベクター
|
|
HUE060949T2
(hu)
|
2018-10-29 |
2023-04-28 |
Inst Nat Sante Rech Med |
Koleszterin 24-hidroláz expressziós vektor amiotrófiás laterálszklerózis kezelésében
|
|
US20210393713A1
(en)
*
|
2018-11-20 |
2021-12-23 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for targeting the blood-brain barrier
|
|
WO2020150556A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
CN110437317B
(zh)
*
|
2019-01-30 |
2023-05-02 |
上海科技大学 |
具有变异衣壳蛋白的腺相关病毒及其用途
|
|
EP3917945A4
(en)
*
|
2019-01-30 |
2023-02-08 |
The Broad Institute Inc. |
ADVANCED ADENO-ASSOCIATED VIRUS (AAVS) TARGETED DELIVERY SYSTEMS
|
|
JP2022523719A
(ja)
*
|
2019-01-31 |
2022-04-26 |
オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ |
Ａａｖキャプシドの転写依存性定方向進化を使用するための方法
|
|
EP3923995A4
(en)
*
|
2019-02-15 |
2023-05-17 |
Allen Institute |
ARTIFICIAL EXPRESSION RECOMBINANTS FOR THE SELECTIVE MODULATION OF GENE EXPRESSION IN SELECTED NEURON CELL POPULATIONS
|
|
KR20220011616A
(ko)
|
2019-03-21 |
2022-01-28 |
스트라이드바이오 인코포레이티드 |
재조합 아데노 관련 바이러스 벡터
|
|
CN113874387B
(zh)
*
|
2019-03-28 |
2025-01-07 |
总医院公司 |
用于转基因表达的工程化腺相关病毒(aav)载体
|
|
JP2022526018A
(ja)
*
|
2019-04-11 |
2022-05-20 |
カリフォルニア インスティテュート オブ テクノロジー |
脳内への特異性が増強されたウイルス組成物
|
|
GB201905301D0
(en)
|
2019-04-15 |
2019-05-29 |
Ospedale San Raffaele Srl |
Gene therapy
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2020223274A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
JP7585233B2
(ja)
*
|
2019-04-30 |
2024-11-18 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ポンペ病の治療のために有用な組成物
|
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
EP3972631B1
(en)
*
|
2019-05-21 |
2024-07-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome
|
|
US20220281922A1
(en)
*
|
2019-08-02 |
2022-09-08 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
US20220290182A1
(en)
|
2019-08-09 |
2022-09-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
US20220364114A1
(en)
|
2019-08-26 |
2022-11-17 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
CA3151087A1
(en)
*
|
2019-08-29 |
2021-03-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adeno-associated viral vectors for crossing the human blood brain barrier
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
GB201912863D0
(en)
*
|
2019-09-06 |
2019-10-23 |
Babraham Inst |
Novel method
|
|
GB201913974D0
(en)
*
|
2019-09-27 |
2019-11-13 |
King S College London |
Vector
|
|
US20230392163A1
(en)
*
|
2019-10-17 |
2023-12-07 |
Ginkgo Bioworks Inc. |
Adeno-associated viral vectors for treatment of niemann-pick disease type c
|
|
US20210162002A1
(en)
*
|
2019-10-17 |
2021-06-03 |
The Penn State Research Foundation |
Regenerating functional neurons for treatment of spinal cord injury and als
|
|
IL292264B2
(en)
*
|
2019-10-17 |
2025-10-01 |
Stridebio Inc |
aav transfer cassette
|
|
EP4061946A4
(en)
*
|
2019-11-19 |
2024-03-06 |
Asklepios Biopharmaceutical, Inc. |
THERAPEUTIC ADENO-ASSOCIATED VIRUS INCLUDING LIVER-SPECIFIC PROMOTERS TO TREAT PUMP DISEASE AND LYSOSOMAL DISORDERS
|
|
CN115023242B
(zh)
*
|
2019-11-22 |
2025-03-14 |
费城儿童医院 |
腺相关病毒载体变体
|
|
WO2021142300A2
(en)
|
2020-01-10 |
2021-07-15 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
|
|
WO2021163357A2
(en)
|
2020-02-13 |
2021-08-19 |
Tenaya Therapeutics, Inc. |
Gene therapy vectors for treating heart disease
|
|
IL295529A
(en)
|
2020-02-13 |
2022-10-01 |
Tenaya Therapeutics Inc |
Gene therapy vectors for treating heart disease
|
|
BR112022021134A2
(pt)
*
|
2020-04-20 |
2023-02-14 |
Tenaya Therapeutics Inc |
Vírus adeno-associado com capsídeo projetado
|
|
CN112011571A
(zh)
*
|
2020-04-26 |
2020-12-01 |
辉大(上海)生物科技有限公司 |
一种用于治疗脊髓性肌萎缩的基因治疗药物
|
|
CA3181011A1
(en)
*
|
2020-04-28 |
2021-11-04 |
Genethon |
Use of a synthetic aav capsid for gene therapy of muscle and central nervous system disorders
|
|
EP4150626A1
(en)
|
2020-04-29 |
2023-03-22 |
The Broad Institute Inc. |
Machine learning accelerated protein engineering through fitness prediction
|
|
CN115867646A
(zh)
*
|
2020-05-01 |
2023-03-28 |
博德研究所 |
工程化中枢神经系统组合物
|
|
KR20230022175A
(ko)
|
2020-05-13 |
2023-02-14 |
보이저 테라퓨틱스, 인크. |
Aav 캡시드의 향성 방향변경
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
GB202010981D0
(en)
|
2020-07-16 |
2020-09-02 |
Ucl Business Ltd |
Gene therapy for neuromuscular and neuromotor disorders
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
US20230227802A1
(en)
|
2020-07-27 |
2023-07-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
GB202011871D0
(en)
*
|
2020-07-30 |
2020-09-16 |
Cambridge Entpr Ltd |
Composition and method
|
|
US20230257431A1
(en)
|
2020-08-05 |
2023-08-17 |
Spacecraft Seven, Llc |
Csrp3 (cysteine and glycine rich protein 3) gene therapy
|
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
EP4192487A4
(en)
|
2020-08-07 |
2024-10-02 |
Spacecraft Seven, LLC |
GENE THERAPY FOR PLAKOPHILIN-2 (PKP2) INVOLVING AAV VECTOR
|
|
MX2023001998A
(es)
|
2020-08-17 |
2023-05-04 |
Massachusetts Inst Technology |
Enfoques de terapia con el gen shank3.
|
|
KR20230068444A
(ko)
|
2020-08-19 |
2023-05-17 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
레트 증후군의 치료를 위한 아데노 관련 바이러스 벡터
|
|
CA3192600A1
(en)
*
|
2020-08-21 |
2022-02-24 |
Capsida, Inc. |
Adeno-associated virus compositions having preferred expression levels
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
WO2022061378A2
(en)
*
|
2020-09-21 |
2022-03-24 |
Asklepios Biopharmaceutical, Inc. |
Methods for treating neurological disease
|
|
CN112194706B
(zh)
*
|
2020-09-30 |
2022-03-08 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
AR123776A1
(es)
|
2020-10-15 |
2023-01-11 |
Hoffmann La Roche |
Construcciones de ácido nucleico para la activación simultánea de genes
|
|
WO2022101363A1
(en)
|
2020-11-11 |
2022-05-19 |
European Molecular Biology Laboratory |
Modified viral particles for gene therapy
|
|
EP4256065A2
(en)
|
2020-12-01 |
2023-10-11 |
The Trustees of The University of Pennsylvania |
Novel compositions with tissue-specific targeting motifs and compositions containing same
|
|
EP4301768A2
(en)
|
2021-03-03 |
2024-01-10 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
JP2024511808A
(ja)
*
|
2021-03-29 |
2024-03-15 |
南京大学 |
ウイルスベクターに基づくｒｎａ送達システム及びその使用
|
|
WO2022221421A2
(en)
*
|
2021-04-13 |
2022-10-20 |
Capsida, Inc. |
Aav compositions with high brain expression for treating mucopolysaccharidosis ii
|
|
WO2022221529A1
(en)
|
2021-04-16 |
2022-10-20 |
Asklepios Biopharmaceutical, Inc. |
Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
|
|
CA3216004A1
(en)
|
2021-04-23 |
2022-10-27 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
|
WO2023283649A1
(en)
|
2021-07-08 |
2023-01-12 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
|
US20240382617A1
(en)
*
|
2021-09-21 |
2024-11-21 |
Capsida Biotherapeutics, Inc. |
Virus compositions to efficiently target the nervous system and the lungs
|
|
KR20240095539A
(ko)
|
2021-10-08 |
2024-06-25 |
디노 테라퓨틱스, 인코포레이티드 |
캡시드 변이체 및 이의 사용 방법
|
|
EP4422613A1
(en)
|
2021-10-25 |
2024-09-04 |
Novartis AG |
Methods for improving adeno-associated virus (aav) delivery
|
|
US20250001012A1
(en)
|
2021-11-02 |
2025-01-02 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
TW202325850A
(zh)
|
2021-11-29 |
2023-07-01 |
大陸商上海瑞宏迪醫藥有限公司 |
Aadc、gdnf多核苷酸及其用於治療帕金森病
|
|
CN114107231B
(zh)
*
|
2021-12-13 |
2023-08-18 |
重庆大学 |
实现全脑突触后神经元胞体标记的重组腺相关病毒及其应用
|
|
EP4469585A2
(en)
|
2022-01-25 |
2024-12-04 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
CN116554278A
(zh)
*
|
2022-01-30 |
2023-08-08 |
上海玮美基因科技有限责任公司 |
变异型腺相关病毒及其在疾病治疗中的应用
|
|
TW202342526A
(zh)
|
2022-02-21 |
2023-11-01 |
大陸商上海瑞宏迪醫藥有限公司 |
Ｖｅｇｆ結合分子及其醫藥用途
|
|
WO2023164545A1
(en)
|
2022-02-23 |
2023-08-31 |
Massachusetts Institute Of Technology |
Methods for upregulating shank3 expression
|
|
IL316430A
(en)
*
|
2022-04-22 |
2024-12-01 |
Childrens Hospital Philadelphia |
HUMAN EPENDYMA-SPECIFIC PROMOTER AND ITS USES
|
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
|
WO2023240236A1
(en)
*
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
TW202421787A
(zh)
|
2022-09-06 |
2024-06-01 |
美商特納亞治療股份有限公司 |
保護心臟之心臟病療法
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
GB2622629A
(en)
|
2022-09-23 |
2024-03-27 |
Sania Rx Ltd |
Method
|
|
EP4615492A1
(en)
|
2022-11-08 |
2025-09-17 |
Ospedale San Raffaele S.r.l. |
Polynucleotide and vector
|
|
EP4669330A1
(en)
|
2023-02-21 |
2025-12-31 |
Institut National de la Santé et de la Recherche Médicale |
METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SANFILIPPO SYNDROME TYPE IIIB
|
|
CN120936709A
(zh)
*
|
2023-03-09 |
2025-11-11 |
新加坡科技研究局 |
经工程化以增强组织转导和特异性的腺相关病毒的新组合物
|
|
AU2024234833A1
(en)
|
2023-03-10 |
2025-10-23 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2024194491A1
(en)
|
2023-03-22 |
2024-09-26 |
Ospedale San Raffaele S.R.L. |
Gene therapy
|
|
WO2024199478A1
(en)
*
|
2023-03-31 |
2024-10-03 |
Exegenesis Bio Co. |
Variant aav9 capsid proteins and uses thereof
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024229389A1
(en)
*
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2024229425A1
(en)
*
|
2023-05-04 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024233422A1
(en)
|
2023-05-05 |
2024-11-14 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
|
WO2024238807A2
(en)
|
2023-05-16 |
2024-11-21 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
TW202516019A
(zh)
|
2023-06-29 |
2025-04-16 |
賓州大學委員會 |
具中樞神經系統靶向模體的突變aav及含有其之組成物
|
|
WO2025021839A1
(en)
|
2023-07-25 |
2025-01-30 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat metabolic disorders
|
|
WO2025032158A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat tauopathies
|
|
TW202525832A
(zh)
|
2023-08-31 |
2025-07-01 |
美商戴諾治療公司 |
衣殼多肽及其使用方法(二)
|
|
CN117264912A
(zh)
*
|
2023-09-25 |
2023-12-22 |
中国科学院深圳先进技术研究院 |
一种重组腺相关病毒颗粒、重组腺相关病毒载体系统及其应用
|
|
WO2025073890A1
(en)
|
2023-10-06 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Method to capture circulating tumor extracellular vesicles
|
|
GB202316264D0
(en)
|
2023-10-24 |
2023-12-06 |
Ospendale San Raffaele S R L |
Gene therapy
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
WO2025106874A1
(en)
*
|
2023-11-15 |
2025-05-22 |
Genzyme Corporation |
Methods of treating neurodegenerative disorders
|
|
WO2025157848A1
(en)
|
2024-01-23 |
2025-07-31 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the intravenous treatment of sanfilippo syndrome type iiib
|
|
WO2025171227A1
(en)
|
2024-02-08 |
2025-08-14 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2025186293A1
(en)
|
2024-03-06 |
2025-09-12 |
Institut National de la Santé et de la Recherche Médicale |
Chmp2b mutants for use for treating infection
|
|
GB202406331D0
(en)
|
2024-05-07 |
2024-06-19 |
Sania Rx Ltd |
Capsid
|